Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

NULL
   
  • Closing Price Chg:
    -30.00p
  • 52 Week High: NULL
  • 52 Week Low: 1,424.00p
  • Currency: UK Pounds
  • Shares Issued: 66.04m
  • Volume: 0
  • RiskGrade: 128

Genus sees FY profit at top end of expectations after strong H1

By Michele Maatouk

Date: Wednesday 15 Jan 2025

LONDON (ShareCast) - (Sharecast News) - Animal genetics firm Genus said on Wednesday that it expects full-year adjusted pre-tax profit to be at the top end of the range of market forecasts after a strong first half.
Consensus expectations are for a range of between £63m and £67.4m.

In an update for the six months to the end of December, Genus said it expects first-half adjusted pre-tax profit of £35m, which is ahead of expectations.

The group said that since its AGM trading update in November, the ABS division has continued to deliver in line with expectations, with adjusted operating profit growth driven mainly by Value Acceleration Programme initiatives.

In addition, PIC - its global porcine genetics business - has traded ahead of expectations thanks to greater volume and adjusted operating profit growth in both the Americas and Asia.

Genus said the regulatory process in relation to its innovative Porcine Reproductive and Respiratory Syndrome Resistant Pig programme continues to progress with both the US Food and Drug Administration and other international regulators.

Genus is due to report its interim results on 27 February.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Genus Market Data

Currency UK Pounds
Share Price NULL
Closing Price Change -30.00p
% Change 0.00 %
52 Week High NULL
52 Week Low 1,424.00p
Volume 0
Shares Issued 66.04m
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.41% below the market average92.41% below the market average92.41% below the market average92.41% below the market average92.41% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
68.43% above the market average68.43% above the market average68.43% above the market average68.43% above the market average68.43% above the market average
91.11% above the sector average91.11% above the sector average91.11% above the sector average91.11% above the sector average91.11% above the sector average
Income
98.32% below the market average98.32% below the market average98.32% below the market average98.32% below the market average98.32% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
91.96% below the market average91.96% below the market average91.96% below the market average91.96% below the market average91.96% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

What The Brokers Say

Strong Buy 6
Buy 2
Neutral 0
Sell 1
Strong Sell 0
Total 9
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 06-Mar-25 07-Nov-24
Paid 04-Apr-25 06-Dec-24
Amount 10.30p 21.70p

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

Genus Key Personnel

CEO Jorgen Kokke

Top of Page